Nucleai AI-Driven Spatial Biomarker Platform

Nucleai's AI-Driven Spatial Biomarker Platform is a next-generation multimodal solution designed to analyze and interpret complex cellular interactions within patient biopsies. Leveraging military intelligence-grade geospatial AI methods, the platform translates spatial biology data into actionable insights that accelerate the development of life-saving treatments and diagnostics. It is built for biopharma organizations, research institutions, and clinical trial teams seeking to power precision therapeutics with advanced spatial biomarker capabilities.

Nucleai partners with leading research institutions to unite multimodal AI technology and spatial biology, identifying predictive biomarkers and translating discoveries into real-world diagnostic solutions. The platform has been adopted by more than 12 of the top 20 biopharma companies, supports over 25 clinical trial studies, and has achieved prospective trial enrollment — notably recognized as the first spatial AI tool used by pathologists for clinical trial patient selection directly connected to a drug development program.

Core Solutions

• Biomarker Discovery & Validation: Identify and validate novel spatial biomarkers from complex tissue data.
• Biomarker Scoring: Optimize and standardize biomarker scoring workflows using AI-driven analysis.
• Genomic Biomarker Screening: Screen for genomic biomarkers to support targeted therapy development.
• Mechanism of Action (MoA): Determine and characterize the mechanism of action of therapeutic candidates through spatial analysis.
• Data Enrichment: Enhance existing datasets with spatial and cellular context to improve analytical depth.
• Companion Diagnostics: Develop and deploy companion diagnostics to support patient stratification and treatment decisions.

AI Technology Capabilities

• Ingests images from multiple modalities including H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics.
• Conducts advanced spatial analysis of cellular interactions within biopsy tissue.
• Delivers actionable insights that optimize biomarker scoring and determine biomarker prevalence.
• Characterizes mechanism of action (MoA) at the cellular and spatial level.
• Predicts patient response to therapy, supporting more informed treatment decisions.
• Provides a first-of-its-kind multimodal spatial AI solution spanning translational research through to diagnostics.

Platform Approach

• Generates dynamic, AI-guided spatial maps of patient biopsies to reflect the complexity and uniqueness of individual biology.
• Supports the full drug development continuum, from early translational research to clinical companion diagnostics.
• Brings together expertise across pathology, medicine, biology, engineering, and artificial intelligence.
• Backed by institutional data partners and strategic investors, including M Ventures, the corporate strategic venture arm of Merck KGaA.

Nucleai's platform is designed for integration into clinical trial workflows and biopharma drug development programs, with an established network of data and institutional partners supporting its deployment across the precision medicine landscape.